Table 4.
Baseline characteristics and clinicopathological information of Triple-Negative and Luminal-like BC patients.
| TNBC* | Luminal-like** | *p-value | **p-value | |||
|---|---|---|---|---|---|---|
| WT | BRCA1/2 | WT | BRCA1/2 | |||
| Number of patients (502) | 120 (77.9%) | 34 (22.1%) | 302 (86.8%) | 46 (13.2%) | - | - |
| Age at diagnosis (y): | ||||||
| Median | 48 | 43 | 41 | 40 | 0.013 | 0.308 |
| Mean | 48.25 | 43.7 | 43.6 | 42.8 | ||
| Range | 30–70 | 28–62 | 21–84 | 30–80 | ||
| Age groups (y) | ||||||
| ⩽ 40 | 30 (25%) | 12 (35.3%) | 140 (46.3%) | 27 (58%) | 0.135 | 0.580 |
| 41–50 | 43 (35.8%) | 16 (47.1%) | 86 (28.4%) | 9 (20%) | ||
| 51–60 | 36 (30%) | 5 (14.7%) | 49 (16.2%) | 6 (13%) | ||
| >60 | 11 (9.2%) | 1 (2.9%) | 27 (9.1%) | 4 (9%) | ||
| Histological Subtype | ||||||
| Ductal | 119 (99.2%) | 33 (97%) | 237 (78.5%) | 36 (78.2%) | 0.337 | 0.700 |
| Lobular | 0 (%) | 0 (%) | 32 (10.6%) | 7 (15.2%) | ||
| Others | 1 (0.8%) | 1 (3%) | 30 (9.9%) | 3 (6.6%) | ||
| unknown | \ | \ | 3 (1%) | \ | ||
| ER (%) | ||||||
| ⩽20 | 14 (4.6%) | 8 (17.4%) | - | 0.001 | ||
| >20 | 267 (88.5%) | 34 (73.9%) | ||||
| unknown | \ | \ | 21 (6.9%) | 4 (8.7%) | ||
| PR (%) | ||||||
| ⩽20 | 60 (19.9%) | 19 (41.3%) | - | 0.007 | ||
| >20 | 211 (69.9%) | 23 (50%) | ||||
| unknown | \ | \ | 31 (10.2%) | 4 (8.7%) | ||
| HER2 (%) | ||||||
| pos | \ | \ | 63 (20.9%) | 4 (8.7%) | - | 0.048 |
| neg | 220 (72.8%) | 42 (91.3%) | ||||
| unknown | 19 (6.3%) | / | ||||
| Ki-67 (%) | ||||||
| <20 | 10 (8.3%) | 2 (5.9%) | 105 (34.8%) | 6 (13%) | 0.854 | <0.001 |
| 20–50 | 34 (28.4%) | 9 (26.5%) | 120 (39.7%) | 21 (45.7%) | ||
| >50 | 76 (63.3%) | 23 (67.6) | 39 (12.9%) | 15 (32.6%) | ||
| unknown | \ | \ | 38 (12.6%) | 4 (8.7%) | ||
| Histological grade | ||||||
| G1 | 4 (3.3) | 1 (2.9%) | 43 (14.3%) | 1 (2.2%) | 0.882 | <0.001 |
| G2 | 18 (15%) | 4 (11.8%) | 141 (46.7%) | 14 (30.4%) | ||
| G3 | 98 (81.7%) | 29 (85.3%) | 84 (27.8%) | 26 (56.5%) | ||
| unknown | \ | \ | 34 (11.2%) | 5 (10.9%) | ||
| Tumor size (T) | ||||||
| T1 | 74 (61.7%) | 18 (53%) | 142 (47.1%) | 19 (41.3%) | 0.802 | 0.920 |
| T2 | 34 (28.3%) | 12 (35.3%) | 77 (25.6%) | 10 (21.7%) | ||
| T3 | 10 (8.3%) | 3 (8.8%) | 5 (1.7%) | / | ||
| T4 | 2 (1.7%) | 1 (2.9%) | 4 (1.4%) | 1 (2.2%) | ||
| unknown | \ | \ | 73 (24.2%) | 16 (34.8%) | ||
| Axillary nodal involvement (N) | ||||||
| N0 | 88 (73.3%) | 13 (38.2%) | 126 (41.7%) | 16 (34.8%) | 0.002 | 0.016 |
| N1 | 22 (18.3%) | 14 (41.3%) | 66 (21.9%) | 10 (21.7%) | ||
| N2 | 8 (6.7%) | 6 (17.6%) | 13 (4.3%) | 2 (4.4%) | ||
| N3 | 2 (1.7%) | 1 (2.9%) | 4 (1.3%) | 4 (8.7%) | ||
| unknown | \ | \ | 93 (30.8%) | 14 (30.4%) | ||
| Bilateral | ||||||
| Yes | 12 (10%) | 5 (14.7%) | 66 (21.8%) | 13 (28.2%) | 0.439 | 0.425 |
| No | 108 (90%) | 29 (85.3%) | 236 (78.2%) | 33 (71.8%) | ||
| Median age at diagnosis (y) | ||||||
| Primary tumor | 48 | 40 | 48 | 41 | 0.033 | 0.0474 |
| Secondary tumor | 56 | 50 | 53 | 52 | ||
| Time between 1st and 2nd tumors (y) | ||||||
| Median | 6.5 | 10 | 3 | 4 | 0.389 | 0.465 |
*
Comparison TNBC WT versus BRCA1/2; **Comparison luminal-like WT versus BRCA1/2.